Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962109 | 0.87 | FPR1 (0.32) | FPR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL25067035 | 0.82 | PIK3CD (0.30) | — | |
| SCHEMBL21962228 | 0.82 | PIK3CD (0.30) | — | |
| SCHEMBL22015041 | 0.74 | FPR1 (0.32) | FPR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL22014738 | 0.74 | P2RX7 (0.33) | FPR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL25067163 | 0.73 | FPR1 (0.31) | FPR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL25066970 | 0.73 | FPR1 (0.31) | FPR1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL22282348 | 0.72 | ALDH1A1 (0.35) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL21962069 | 0.70 | SLC16A3 (0.30) | — | |
| SCHEMBL25067075 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880658-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |